⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 16, 2024

Figure S11 from Treatment of prostate cancer with CD46 targeted ²²⁵Ac alpha particle radioimmunotherapy

Anil P. Bidkar Sinan Wang Kondapa Naidu Bobba Emily Chan Scott Bidlingmaier Emily A. Egusa Robin Peter Umama Ali Niranjan Meher Anju Wadhwa Suchi Dhrona Chandrashekhar Dasari Denis Beckford-Vera Yang Su Ryan Tang Li Zhang Jiang He David M. Wilson Rahul Aggarwal Henry F. VanBrocklin Youngho Seo Jonathan Chou Bin Liu Robert R. Flavell

View at Publisher

Ask AI

Bookmark

Share

Abstract

Figure S11: Antitumor activity of [225Ac]DOTA-YS5 in subcutaneous DU145 tumors in nude mice. Tumor volume, survival analysis, and weight measurements after the injections of [225Ac]DOTA-YS5 in DU145 xenografts (n=6).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bidkar et al. (2024) studied this question.

synapsesocial.com/papers/68e586c1b6db6435875239cc https://doi.org/10.1158/1078-0432.27030406.v1

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S8 from Treatment of prostate cancer with CD46 targeted <sup>225</sup>Ac alpha particle radioimmunotherapy2024
2Figure S7 from Treatment of prostate cancer with CD46 targeted <sup>225</sup>Ac alpha particle radioimmunotherapy2024
3Data from Treatment of prostate cancer with CD46 targeted <sup>225</sup>Ac alpha particle radioimmunotherapy2024
4Figure S3 from Treatment of prostate cancer with CD46 targeted <sup>225</sup>Ac alpha particle radioimmunotherapy2024
5Figure S2 from Treatment of prostate cancer with CD46 targeted <sup>225</sup>Ac alpha particle radioimmunotherapy2024

More related papers

Figure S9 from Treatment of prostate cancer with CD46 targeted <sup>225</sup>Ac alpha particle radioimmunotherapy2024
Figure S4 from Treatment of prostate cancer with CD46 targeted <sup>225</sup>Ac alpha particle radioimmunotherapy2024
Figure S6 from Treatment of prostate cancer with CD46 targeted <sup>225</sup>Ac alpha particle radioimmunotherapy2024